Elite Pharmaceuticals Inc (ELTP)

[jour_trader]

That’s a very valid question. The $5.1B figure would exclude any generics as they were just approved and IQVIA wouldn’t have any generic data included, but by how much does the total market potential decrease because of the significant shift away from branded to lower price generic? 30%, 40%? I haven’t researched this, but there may also be some volume shift to generic Vyvanse to stabilize CNS market.

On separate but similar note, Oxy will be in the same boat is it potentially shifts to generic, however, we know Elite is among first filers and may indeed be the first to file. We will know soon enough.